1. Scrip
  2. >>New Products

Rinvoq Approved For Crohn’s Disease In Pivotal Year For AbbVie’s Immunology Business

7th US Indication For The JAK Inhibitor, 2nd In IBD

 
• By Mandy Jackson

US FDA approval in Crohn’s disease further boosts the revenue potential for Rinvoq as AbbVie navigates a period of declining sales overall due to the introduction of US biosimilars for Humira. 

Intestines health. Guts on pink background top view copy space
Rinvoq is now approved in the US for two inflammatory bowel disease indications • Source: Shutterstock

The US Food and Drug Administration approval of AbbVie Inc.’s Rinvoq (upadacitinib) for Crohn’s disease is the drug’s second inflammatory bowel disease (IBD) indication and seventh indication overall, increasing the JAK inhibitor’s revenue potential at a crucial time for the company. Sales for Humira (adalimumab) are in decline with the introduction of the first US biosimilars of the top-seller in AbbVie’s powerhouse immunology franchise, resulting in lower overall revenue for the company in 2023.

AbbVie hopes that combined sales of Rinvoq and the interleukin-23 inhibitor Skyrizi (risankizumab) will eventually fill the Humira revenue deficit. The company has guided for $11.1bn in sales from the two products this year, and it expects a 37% decline in Humira revenue from $21.2bn in 2022. (Also see "AbbVie Pinpoints US Humira Erosion At 37% In 2023" - Scrip, 9 February, 2023.) The company forecast $17

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

More from Scrip

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, and Lisa Takagi

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.